627 related articles for article (PubMed ID: 28764555)
21. Escalation with overdose control using all toxicities and time to event toxicity data in cancer Phase I clinical trials.
Chen Z; Cui Y; Owonikoko TK; Wang Z; Li Z; Luo R; Kutner M; Khuri FR; Kowalski J
Contemp Clin Trials; 2014 Mar; 37(2):322-32. PubMed ID: 24530487
[TBL] [Abstract][Full Text] [Related]
22. A utility-based Bayesian optimal interval (U-BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies.
Zhou Y; Lee JJ; Yuan Y
Stat Med; 2019 Dec; 38(28):5299-5316. PubMed ID: 31621952
[TBL] [Abstract][Full Text] [Related]
23. Competing designs for drug combination in phase I dose-finding clinical trials.
Riviere MK; Dubois F; Zohar S
Stat Med; 2015 Jan; 34(1):1-12. PubMed ID: 24464821
[TBL] [Abstract][Full Text] [Related]
24. A new approach to integrate toxicity grade and repeated treatment cycles in the analysis and reporting of phase I dose-finding trials.
Doussau A; Thiébaut R; Geoerger B; Schöffski P; Floquet A; Le Deley MC; Mathoulin-Pélissier S; Rizzo E; Fumoleau P; Le Tourneau C; Paoletti X
Ann Oncol; 2015 Feb; 26(2):422-8. PubMed ID: 25403589
[TBL] [Abstract][Full Text] [Related]
25. Efficacy/toxicity dose-finding using hierarchical modeling for multiple populations.
Cunanan KM; Koopmeiners JS
Contemp Clin Trials; 2018 Aug; 71():162-172. PubMed ID: 29936124
[TBL] [Abstract][Full Text] [Related]
26. Performance of toxicity probability interval based designs in contrast to the continual reassessment method.
Horton BJ; Wages NA; Conaway MR
Stat Med; 2017 Jan; 36(2):291-300. PubMed ID: 27435150
[TBL] [Abstract][Full Text] [Related]
27. A novel framework of Bayesian optimal interval design for phase I trials with late-onset toxicities.
Zhou H; Chen C; Sun L; Zeng Z
Contemp Clin Trials; 2021 Jun; 105():106404. PubMed ID: 33862287
[TBL] [Abstract][Full Text] [Related]
28. Early phase trial designs and endpoints for targeted therapies in rare genotype subsets.
Mandrekar SJ
Am Soc Clin Oncol Educ Book; 2014; ():e107-10. PubMed ID: 24857087
[TBL] [Abstract][Full Text] [Related]
29. Adaptive dose-finding based on safety and feasibility in early-phase clinical trials of adoptive cell immunotherapy.
Wages NA; Fadul CE
Clin Trials; 2020 Apr; 17(2):157-165. PubMed ID: 31856602
[TBL] [Abstract][Full Text] [Related]
30. Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study.
Postel-Vinay S; Collette L; Paoletti X; Rizzo E; Massard C; Olmos D; Fowst C; Levy B; Mancini P; Lacombe D; Ivy P; Seymour L; Le Tourneau C; Siu LL; Kaye SB; Verweij J; Soria JC
Eur J Cancer; 2014 Aug; 50(12):2040-9. PubMed ID: 24880774
[TBL] [Abstract][Full Text] [Related]
31. Identifying a maximum tolerated contour in two-dimensional dose finding.
Wages NA
Stat Med; 2017 Jan; 36(2):242-253. PubMed ID: 26910586
[TBL] [Abstract][Full Text] [Related]
32. An adaptive dose-finding approach for correlated bivariate binary and continuous outcomes in phase I oncology trials.
Hirakawa A
Stat Med; 2012 Mar; 31(6):516-32. PubMed ID: 22108785
[TBL] [Abstract][Full Text] [Related]
33. An adaptive gBOIN design with shrinkage boundaries for phase I dose-finding trials.
Mu R; Hu Z; Xu G; Pan H
BMC Med Res Methodol; 2021 Dec; 21(1):278. PubMed ID: 34895153
[TBL] [Abstract][Full Text] [Related]
34. The performance of model-based versus rule-based phase I clinical trials in oncology : A quantitative comparison of the performance of model-based versus rule-based phase I trials with molecularly targeted anticancer drugs over the last 2 years.
van Brummelen EM; Huitema AD; van Werkhoven E; Beijnen JH; Schellens JH
J Pharmacokinet Pharmacodyn; 2016 Jun; 43(3):235-42. PubMed ID: 26960536
[TBL] [Abstract][Full Text] [Related]
35. A comparison of model choices for the Continual Reassessment Method in phase I cancer trials.
Paoletti X; Kramar A
Stat Med; 2009 Oct; 28(24):3012-28. PubMed ID: 19672839
[TBL] [Abstract][Full Text] [Related]
36. Optimal phase I dose-escalation trial designs in oncology--a simulation study.
Gerke O; Siedentop H
Stat Med; 2008 Nov; 27(26):5329-44. PubMed ID: 17849502
[TBL] [Abstract][Full Text] [Related]
37. CRM2DIM: A SAS macro for implementing the dual-agent Bayesian continual reassessment method.
Bayar MA; Ivanova A; Le Teuff G
Comput Methods Programs Biomed; 2019 Jul; 176():211-223. PubMed ID: 31200907
[TBL] [Abstract][Full Text] [Related]
38. BOIN-ET: Bayesian optimal interval design for dose finding based on both efficacy and toxicity outcomes.
Takeda K; Taguri M; Morita S
Pharm Stat; 2018 Jul; 17(4):383-395. PubMed ID: 29700965
[TBL] [Abstract][Full Text] [Related]
39. phase1RMD: An R package for repeated measures dose-finding designs with novel toxicity and efficacy endpoints.
Yin J; Du Y; Qin R; Shen S; Mandrekar S
PLoS One; 2021; 16(9):e0256391. PubMed ID: 34473708
[TBL] [Abstract][Full Text] [Related]
40. Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program.
Drilon A; Eaton AA; Schindler K; Gounder MM; Spriggs DR; Harris P; Ivy SP; Iasonos A; Lacouture ME; Hyman DM
Cancer; 2016 Apr; 122(8):1228-37. PubMed ID: 26916138
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
